Pioneering fully individualized TCR therapies for cancer

Our Mission

Neogene Therapeutics is a global, preclinical stage biotechnology company pioneering the development of next generation, fully individualized engineered T cell therapies for a broad spectrum of cancers.

Our proprietary neoantigen T cell receptor (TCR) discovery and T cell engineering platform identifies TCR genes with specificity for neoantigens – found exclusively on cancer cells as a result of cancer-associated DNA mutations.

Cancer is a genetically individual disease – no two tumors are exactly the same. These variations create neoantigens – unique targets for every tumor. Neogene’s novel approach delivers a tailored T cell therapy containing a unique set of specific TCR genes for each individual patient. Engineered into patient-derived T cells, these TCRs are directed toward neoantigens in tumor cells, with the goal of eliciting strong and durable responses in a variety of solid tumor indications.

While engineered T cell therapies have transformed the treatment paradigm for patients with hematologic malignancies, effective T cell therapy is limited for solid cancers. To truly revolutionize patient outcomes, we need a new approach to effectively treat and potentially cure solid cancers.

We believe that through a fully individualized approach using patient-specific TCRs to target neoantigens, engineered T cell therapy can become broadly accessible to these patients.

Carsten Linnemann, Ph.D., Chief Executive Officer

Our History

Neogene is built on the premise of innovation and novel paradigm-changing science to enable effective T-cell therapy of solid cancers.

  • September 2018

    Founded in Amsterdam, the Netherlands, by world-class cell therapy experts Ton Schumacher, Ph.D. and Carsten Linnemann, Ph.D. to advance the development of neoantigen T cell therapies.

  • May 2019
  • September 2020

    Raised $110 million Series A financing from marquee group of investors, led by EcoR1, Jeito Capital and Syncona.

  • October 2020
  • May 2021

    Established U.S. headquarters in Santa Monica, CA

  • September 2018
  • May 2019

    Secured seed investment from Bellco Capital, TPG, Two River and Vida Ventures.

  • September 2020
  • October 2020

    Announced strategic partnership with Twist Bioscience to build synthetic TCR libraries.

  • May 2021
  • September 2018

    Founded in Amsterdam, the Netherlands, by world-class cell therapy experts Ton Schumacher, Ph.D. and Carsten Linnemann, Ph.D. to advance the development of neoantigen T cell therapies.

  • May 2019
  • September 2020

    Raised $110 million Series A financing from marquee group of investors, led by EcoR1, Jeito Capital and Syncona.

  • October 2020
  • May 2021

    Established U.S. headquarters in Santa Monica, CA

  • September 2018
  • May 2019

    Secured seed investment from Bellco Capital, TPG, Two River and Vida Ventures.

  • September 2020
  • October 2020

    Announced strategic partnership with Twist Bioscience to build synthetic TCR libraries.

  • May 2021

Our Team

Neogene’s leadership team is comprised of world-leading TCR experts and cell therapy industry veterans with decades of oncology knowledge and experience, who hold a deep commitment to providing innovative therapies to patients with cancer.

Carsten Linneman
Carsten Linnemann, Ph.D.

Chief Executive Officer

Han Lee
Han Lee, Ph.D.

Chief Financial Officer

Christopher Wilfong, MBA

Chief Business Officer

Sean Algeo
Sean Algeo, CPA

Treasurer and Corporate Controller

David Tanen
David M. Tanen

Corporate Secretary

Mauro Avanzi
Mauro P. Avanzi, M.D., Ph.D.

Vice President, Clinical Development

Gavin M. Bendle, Ph.D.
Gavin M. Bendle, Ph.D.

Vice President, Research and Development

Arianne Perez
Arianne Perez Garcia, Ph.D.

Vice President, Translational Sciences

Stephanie Heintz, M.P.H
Stephanie Heintz, M.P.H

Executive Director, Head of Human Resources

Marisa Leonard
Marisa Leonard

Vice President, Head of Business Development

David Lund
David Lund, Ph.D.

Vice President, Intellectual Property

Harish Mundre
Harish Mundre

Vice President, Head of Information Technology

Kanti Thirumoorthy
Kanti Thirumoorthy, Ph.D.

Vice President, Technical Operations

Sanne Weijzen, Ph.D.
Sanne Weijzen

Vice President, Corporate Strategy and EU Operations

Our Team

2018
2019
2020
2021